Ideas For Profit | Will Sun Pharma’s steady India business, US speciality portfolio help it do well in FY22?

Ideas For Profit | Will Sun Pharma’s steady India business, US speciality portfolio help it do well in FY22?
In this edition of Ideas For Profit, Moneycontrol#39;s Sakshi Batra decodes Sun Pharma Q1 results and suggests what strategy investors could adopt now.